Stock IRLAB A IRLAB THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Delayed Nasdaq Stockholm
Other stock markets
 03:59:49 2024-04-30 am EDT 		5-day change 1st Jan Change
11.5 SEK +2.22% Intraday chart for IRLAB Therapeutics AB 0.00% +53.33%
Mar. 22 IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam CI
Mar. 19 IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
IRLAB THERAPEUTICS AB Stock IRLAB Therapeutics AB
+53.33% 53.39M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.70% 567B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.42% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.10% 196B
A+
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IRLAB A Stock
  4. Ratings IRLAB Therapeutics AB